|
Mar 13
|
KORU Medical Systems, Inc. Announces 2023 Fourth Quarter, Full Year Financial Results, and 2024 Guidance
|
|
Mar 11
|
KORU Medical Systems Announces a Feasibility Study to Enter Ambulatory Infusion Settings with a Commercialized Biologic
|
|
Mar 6
|
KORU Medical Systems Signs a Clinical Supply Agreement for Phase 3 Trial with Leading Pharma Partner Using Custom Device for a Novel Subcutaneous Immunoglobulin
|
|
Nov 29
|
KORU Medical Systems to Participate in Piper Sandler’s 35th Annual Healthcare Conference
|
|
Nov 28
|
KORU Medical Systems, Inc. to Host Investor Day on December 5, 2023
|
|
Nov 8
|
KORU Medical Systems Inc (KRMD) Reports Q3 2023 Financial Results and Updates Full Year Outlook
|
|
Nov 8
|
KORU Medical Systems, Inc. Announces Development Agreement for Next-generation Subcutaneous Immunoglobulin Infusion System
|
|
Nov 8
|
KORU Medical Systems, Inc. Appoints Ken Miller as Chief Commercial Officer
|
|
Nov 8
|
KORU Medical Systems, Inc. Announces 2023 Third Quarter Financial Results and Updates Full Year 2023 Outlook
|
|
Nov 7
|
KORU Medical Systems, Inc. Receives FDA 510(k) Clearance for FREEDOM60® Infusion System With Hizentra® 50 ML Prefilled Syringes
|
|
Nov 2
|
KORU Medical Systems to Participate in Upcoming Investor Conferences
|
|
Aug 9
|
KORU Medical Systems, Inc. Announces 2023 Second Quarter Financial Results and Updates Full Year 2023 Outlook
|
|
Aug 8
|
KORU Medical Systems to Participate in the Genuity 43rd Annual Growth Conference
|
|
Jul 10
|
KORU Medical Systems, Inc. Announces 510(K) Submission for Freedom60® Infusion System With Hizentra® 50 Ml Prefilled Syringes
|